Pfizer ups guidance as it prepares to sell off generics divi...

Pfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared with the same period last year.

Setback in COVID-19 effort as Roche's Actemra fails in key t...

Roche’s anti-inflammatory drug Actemra has failed in a phase 3 clinical trial that was testing to see if it improved the condition of patients with COVID-19 associated pneumonia.

Understanding COVID-19 and varying responses across the glob...

Can llama antibodies beat COVID-19? Belgium's ExeVir raises ...

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round.

Trump's tweets advocate hydroxychloroquine as big COVID-19 v...

Hydroxychloroquine, the anti-malaria drug controversially used to fight COVID-19, was trending again after a string of retweets from president Donald Trump in favour of the medicine.

Brits more comfortable sharing data with pharma since COVID-...

New research from MHP Health and ComRes looks at what impacts COVID-19 has had on the public’s health data sharing concerns, and asks how the industry can maintain confidence in data usage